Skip to main content

Table 1 Participants' demographic data, initial lipids profile, by treatment group

From: Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting

  Group A Group B Group C P* value
Number of patients 62 112 51  
Age (years +/- SD) 47.3 ± 11 46.8 ± 12 51 ± 9.6 NS
Gender (% female) 71 74 61 NS
Ischemic heart disease (%) 0 4 0 NS
Hypertension (%) 44 51 27 P < 0.05
Diabetes mellitus (%) 9 18 20 NS
Dyslipidemia (%) 16 38 66 P < 0.001
Initial body weight     
Initial body mass index (BMI; kg/m2 +/- SD) 33 ± 3.8 34 ± 4.4 31 ± 3.6 P < 0.01
34 > 31(B > C)
Initial triglycerides (mg/dl, +/- SD) 170 ± 53 184 ± 49 255 ± 205 P < 0.01
170 <255> 183
(A < B > C)
Initial low density lipoproteins (LDL; mg/dl, +/- SD) 150 ± 30 156 ± 36 152 ± 44 NS
Initial high density lipoproteins (HDL; mg/dl, +/- SD) 42 ± 7.0 44 ± 6.7 47 ± 14.9 NS
Average length of treatment (weeks, +/- SD) 13 ± 12.0 9 ± 4.7 23 ± 12 P < 0.001
23 > 13 > 9
(C > A > B)
Number of meetings with physician/dietitian (+/- SD) 4.3 ± 2.0 3.5 ± 1.5 5.2 ± 2.9 P < 0.001
5.2 > 3.5 (C > B)
  1. NS = Not significant.
  2. Group A – Orlistat, a personal reduced-energy diet and a meeting with a family practitioner and a clinical dietitian once every two weeks.
  3. Group B – Orlistat, a general formulated reduced-energy diet and follow-up by the family physician once every four weeks.
  4. Group C – a personal low-calorie diet and follow-up by a clinical dietitian once a month.
  5. * When significant statistical differences were found among the three groups, we examined the statistical difference between each group of two.